Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TCA Cellular Therapy has received a Qualifying Therapeutic Discovery Program (QTDP) grant from the US Department of Health and Human Services, for their efforts in developing combination and single adult stem cell therapies with an emphasis on cardiovascular and neurological diseases.
Subscribe to our email newsletter
TCA Cellular Therapy said that the funding will help the company to continue the development of adult stem cell therapies for critical limb ischemia, cardiac ischemia, myocardial infarction, amyotrophic lateral sclerosis (ALS or Lou Gherig’s Disease), and spinal cord injury.
TCA Cellular Therapy president and medical director Gabriel Lasala said that the grant would assist the company in expanding the research for the treatment of multiple diseases and conditions.
QTDP was part of the Patient Protection and Affordable Care Act of 2010 and provides a 50% tax credit or grant to biotech, pharmaceutical and other healthcare companies for qualified investments by eligible companies in taxable years beginning in 2009 and in 2010 in connection with qualifying projects.